Kevin Cole, Ph.D., Junliang Hao, Ph.D.

Kevin Cole, Ph.D.
Senior Research Scientist
Eli Lilly and Company

Junliang Hao, Ph.D.
Research Adviser, Discovery Chemistry
Eli Lilly and Company

Host: Nicholas Race

Discovery and development of mevidalen, a first-in-class positive allosteric modulator of the dopamine D1 receptor

Kevin Cole, Ph.D.
Kevin Cole, Ph.D.

Kevin Cole was born in St. Paul, MN, and received his Bachelor of Science in chemistry from the University of Minnesota in 1999. He stayed at Minnesota for graduate studies, earning a doctorate in 2005, working with Professor Richard Hsung developing novel methodologies to apply to natural product total synthesis. He then moved to The Scripps Research Institute in San Diego to work with Professor K.C. Nicolaou investigating complex natural product synthesis.  In 2007, Cole joined the process development group at Eli Lilly in Indianapolis, IN.  As a principal research scientist, Cole has primarily worked to develop new production routes for early–mid phase clinical assets and has utilized continuous processing to support the supply for a number of clinical assets. 

Junliang Hao
Junliang Hao, Ph.D.

Junliang Hao received his doctorate from University of Minnesota in 2002, and did his post-doctoral researches at The Scripps Research Institute and Harvard University. He started at Eli Lilly at Indianapolis in 2006, and has worked primarily on small molecule drug discovery. More recently, he has worked on RNA therapeutics. He currently holds the title of Research Adviser, and his research has contributed to several clinical candidates that have reached phase two clinical studies, one of which is the first-in-class D1PAM he will share in this seminar.

Category
Special Seminar
Start date
Monday, Sept. 28, 2020, 4 p.m.
End date
Monday, Sept. 28, 2020, 5 p.m.
Location

MS Teams